Cadila Pharma Launches API Manufacturing Plant at Dahej

The total investment to set up this facility is around INR 200 Cr. Further, the facility is designed with advanced technologies including the latest Distributed Control System (DCS) automation technology.

Ahmedabad-based multinational pharmaceutical company Cadila Pharmaceuticals has unveiled its advanced Active Pharmaceutical Ingredients (API) Plant at Dahej.

The total investment to set up this facility is around INR 200 Cr. Further, the facility is designed with advanced technologies including the latest Distributed Control System (DCS) automation technology.

Reportedly, the pharma company has signed a memorandum of understanding (MoU) with the Gujarat Government to invest INR 1,000 Cr over the next three years until 2025.

This investment will be used for expanding the pharma’s existing facilities and enhancing their in-house manufacturing capabilities. The new API plant at Dahej is part of this expansion plan as well, while the other proposed plants are also expected to create direct employment for 500 people by 2025.

Moreover, the newly launched facility is expected to manufacture APIs required for its key selling formulations. This move comes in light of an increase in the prices of APIs due to the shutdown of some Chinese API plants due to pollution concerns.

By setting up this plant, Cadila Pharmaceuticals seeks to ensure a steady supply of APIs for its products, reduce its dependency on external suppliers, and control costs.

Speaking on the occasion, Biswajit Mitra, chief mentoring officer, Cadila Pharmaceuticals and Convener Pharma Panel, CII Gujarat State, said, "The DCS technology used in this facility will allow us to produce APIs with a high level of purity and consistency, while also reducing the environmental impact. This facility is designed to be highly efficient, aiding us in meeting the growing demand for our products. The implementation of the plant project will further extend our impact by generating employment opportunities for both permanent and contractual positions, thereby continuing our dedication to creating positive social change."

Founded in 1951 by Indravadan Modi and Ramanbhai Patel, Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad, Gujarat, India. Cadila Pharmaceuticals’ operations focus on manufacturing products ranging from APIs-Intermediates, finished formulations, OTC-Food supplements, biotechnology Products, and pharmaceutical Machinery. Their manufacturing facilities are approved by International bodies such as WHO-GMP, UK-MHRA, USFDA-API, TGA-Australia, and AIFA-Italy.

Going forward, Cadila Pharmaceuticals aims to continue its research and development in the pharmaceutical field to address various health issues and improve healthcare solutions.

In a similar development, Rusan Pharma launched an API facility in Madhya Pradesh with an INR 300 Cr investment. The facility is designed to meet international regulatory guidelines, ensuring the highest level of compliance. With the production capability of 400 metric tonnes of APIs annually.